2024
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
JOSE, Luis Pinana; Gloria TRIDELLO; Alienor XHAARD; Lotus WENDEL; Juan MONTORO et. al.Basic information
Original name
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
Authors
JOSE, Luis Pinana; Gloria TRIDELLO; Alienor XHAARD; Lotus WENDEL; Juan MONTORO; Lourdes VAZQUEZ; Inmaculada HERAS; Per LJUNGMAN; Malgorzata MIKULSKA; Urpu SALMENNIEMI; Ariadna PEREZ; Nicolaus KROEGER; Jan CORNELISSEN; Elisa SALA; Rodrigo MARTINO; Claire GEURTEN; Jenny BYRNE; Johan MAERTENS; Tessa KERRE; Murray MARTIN; Jesus Pascual MARIA; Moshe YESHURUN; Juergen FINKE; Andreas H GROLL; Peter J SHAW; Nicole BLIJLEVENS; William ARCESE; Arnold GANSER; Maria SUAREZ-LLEDO; Mohsen ALZAHRANI; Goda CHOI; Edouard FORCADE; Annalisa PAVIGLIANITI; Carlos SOLANO; Jacek WACHOWIAK; Tsila ZUCKERMAN; Peter BADER; Johannes CLAUSEN; Jiří MAYER (203 Czech Republic, belonging to the institution); Wilfried SCHROYENS; Elisabetta METAFUNI; Nina KNELANGE; Dina AVERBUCH and de la Camara RAFAEL
Edition
JOURNAL OF INFECTIOUS DISEASES, CARY, OXFORD UNIV PRESS INC, 2024, 0022-1899
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 5.000 in 2023
RIV identification code
RIV/00216224:14110/24:00138805
Organization unit
Faculty of Medicine
UT WoS
001343885600005
EID Scopus
2-s2.0-85168092462
Keywords in English
SARS-CoV-2; allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; human coronavirus; human metapneumovirus; immunocompromised; immunodeficiency score index; multiplex PCR assay
Tags
International impact, Reviewed
Changed: 6/2/2025 10:42, Mgr. Tereza Miškechová
Abstract
V originále
Background Human metapneumovirus (hMPV) epidemiology, clinical characteristics and risk factors for poor outcome after allogeneic stem cell transplantation (allo-HCT) remain a poorly investigated area. Methods This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allo-HCT. Results We included 428 allo-HCT recipients who developed 438 hMPV infection episodes between January 2012 and January 2019. Most recipients were adults (93%). hMPV infections were diagnosed at a median of 373 days after allo-HCT. The infections were categorized as upper respiratory tract disease (URTD) or lower respiratory tract disease (LRTD), with 60% and 40% of cases, respectively. Patients with hMPV LRTD experienced the infection earlier in the transplant course and had higher rates of lymphopenia, neutropenia, corticosteroid use, and ribavirin therapy. Multivariate analysis identified lymphopenia and corticosteroid use (>30 mg/d) as independent risk factors for LRTD occurrence. The overall mortality at day 30 after hMPV detection was 2% for URTD, 12% for possible LRTD, and 21% for proven LRTD. Lymphopenia was the only independent risk factor associated with day 30 mortality in LRTD cases. Conclusions These findings highlight the significance of lymphopenia and corticosteroid use in the development and severity of hMPV infections after allo-HCT, with lymphopenia being a predictor of higher mortality in LRTD cases.